The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02073903
First received: February 24, 2014
Last updated: July 31, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to introduce new technology and interpreter practices in the inpatient setting at MSKCC. We plan to install dual handset phones at the bedsides of limited English proficiency (LEP) patients and to assess the impact on both patient and physician communication effectiveness with this technology.


Condition Intervention
Inpatients With Limited English Proficiency
Behavioral: Patient Survey
Behavioral: Provider Survey

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • Patient communication effectiveness [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    with the dual handset phones assessed by the survey


Secondary Outcome Measures:
  • Physician and nurse communication effectiveness [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    with the dual handset phones assessed by the survey


Estimated Enrollment: 120
Study Start Date: February 2014
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LEP inpatients and their providers
This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
Behavioral: Patient Survey Behavioral: Provider Survey

Detailed Description:

During the first 5-6 weeks of the study there will be no intervention and standard of care will be conducted as usual practice by the medicine teams at MSKCC. It is expected that during that time they will care for at least 20 LEP patients who meet our inclusion criteria. There are no specific target numbers for any of the included languages. During the following 5-6 weeks, the phones will be installed by the 10 house-staff teams and approximately an additional 20 LEP patients who meet the protocol inclusion criteria will be enrolled. Therefore, in the first half of this study about 20 LEP patients and 40 practitioners (two practitioners per LEP patient) will provide data and the same numbers will account for the second half of the study after the intervention is instituted. There will be no randomization of patients or physicians. The only data that will be analyzed are those questions from the surveys to assess communication effectiveness with LEP patients. The number of patients who are interviewed will depend on MSKCC inpatient census at the time of study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • LEP patients identified by the Department of Interpreter Services at MSKCC admitted to the Hepatobiliary surgery service, the Colorectal Surgery service the GMT surgery service, GI, GU, Breast, General Medicine, Leukemia, or Lymphoma services with a primary language of Spanish, Russian, or Mandarin.
  • LEP patients who are expected to have at least a two days hospital course.
  • Patients who are alert and oriented to person, place, and time as determined by the medical doctor taking care of the patient
  • Patients who are willing to participate and complete the survey
  • Patients whose physicians and nurses are willing to participate
  • Only persons ≥ 18 will be included and there will be no children.
  • Providers must be willing to participate and complete the survey
  • TY interns cannot complete provider surveys

Exclusion Criteria:

  • Patients on contact isolation
  • Patients who previously completed the survey
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02073903

Contacts
Contact: Chhavi Kumar, MD 212-639-7927
Contact: Lisa Diamond, MD 646-888-4246

Locations
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Chhavi Kumar, MD    212-639-7927      
Contact: Lisa Diamond, MD    646-888-4246      
Principal Investigator: Chhavi Kumar, MD         
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Chhavi Kumar, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT02073903     History of Changes
Other Study ID Numbers: 14-042
Study First Received: February 24, 2014
Last Updated: July 31, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
dual handset interpreter phones
communication
14-042

ClinicalTrials.gov processed this record on August 28, 2014